drugset
drugset / Trial / NCT02629523

Afatinib in Lung Cancer With EGFR Mutation From Circulating Tumor DNA

NCT02629523 ↗

Phase 2 Completed 21 enrolled Chonnam National University Hospital
NaSingle-groupOpen-labelTreatment

Summary

Treatment efficacy of afatinib will be assessed in patients with lung cancer harboring EGFR mutations which were detected from circulating tumor DNA.

Timeline

Start
2016-06-01
Primary completion
2018-12-31
Completion
2020-05-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Afatinib Small molecule — —

Indications

lung cancer